共 50 条
Antiepileptic treatment with levetiracetam during the first trimester and pregnancy outcome: An observational study
被引:2
|作者:
Hoeltzenbein, Maria
Bartz, Insa
Fietz, Anne-Katrin
Lohse, Lukas
Onken, Marlies
Dathe, Katarina
Schaefer, Christof
机构:
[1] Charite Univ Med Berlin, Embryotox Ctr Clin Teratol & Drug Safety Pregnanc, Inst Clin Pharmacol & Toxicol, Berlin, Germany
[2] Free Univ Berlin, Berlin, Germany
[3] Humboldt Univ, Berlin, Germany
来源:
关键词:
birth defects;
epilepsy;
levetiracetam;
pregnancy outcome;
spontaneous abortion;
PERINATAL SURVEY DATA;
ANTHROPOMETRIC DIMENSIONS;
PERCENTILE VALUES;
NEONATES ANALYSIS;
FETAL-GROWTH;
16;
STATES;
DRUGS;
EPILEPSY;
MALFORMATIONS;
COHORT;
D O I:
10.1111/epi.17800
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
ObjectiveLevetiracetam is increasingly used in pregnant women with epilepsy. Although teratogenic effects have not been observed so far, data on the risks of spontaneous abortion and major birth defects are still limited, especially for the frequently used dual therapy of levetiracetam and lamotrigine. Our primary aim was to analyze rates of major birth defects and spontaneous abortion after maternal levetiracetam treatment.MethodsThis was a cohort study based on pregnancies recorded by the Embryotox Center from 2000 to 2017. Outcomes of prospectively ascertained pregnancies with first trimester levetiracetam monotherapy (n = 221) were compared to pregnancies with lamotrigine monotherapy for epilepsy (n = 469). In addition, all pregnancies with levetiracetam (n = 364) exposure during the first trimester were analyzed in comparison to a nonexposed cohort (n = 729). Pregnancies with the most frequently used combination therapy comprising levetiracetam and lamotrigine (n = 80) were evaluated separately.ResultsThere was no significantly increased risk of major birth defects or of spontaneous abortions after first trimester exposure to levetiracetam. Birth weight of male neonates was significantly lower after levetiracetam monotherapy compared to lamotrigine monotherapy. Dual therapy with levetiracetam and lamotrigine resulted in a significantly increased risk of spontaneous abortion (adjusted hazard ratio = 3.01, 95% confidence interval [CI] = 1.43-6.33) and a nonsignificant effect estimate for major birth defects (7.7%, n = 5/65, adjusted odds ratio = 1.47, 95% CI = .48-4.47) compared to a nonexposed cohort.SignificanceOur study confirms the use of levetiracetam as a suitable antiepileptic drug in pregnancy. The lower birth weight of male neonates after maternal levetiracetam monotherapy and the unexpectedly high risk of spontaneous abortion and birth defects after dual therapy with levetiracetam and lamotrigine require further investigation.
引用
收藏
页码:26 / 36
页数:11
相关论文